Executive Summary
Often termed as “pharmacy of the world”, India’s pharmaceutical sector is transitioning from volume-driven generics leadership to innovation-led growth. With a current market size of ~$60 billion projected to reach $450 billion by 2047, the next phase hinges on investments in R&D, biologics, and new chemical entities.
Government initiatives, increasing private-sector R&D spend, and evolving regulatory frameworks are strengthening this shift. However, challenges such as high development costs, long timelines, and regulatory complexity persist.
To emerge as a global innovation hub, India must accelerate regulatory reforms, scale digital infrastructure, and incentivise high-risk research, transforming momentum into sustained global leadership.
India’s Drug Discovery Ambition
India is primed for a leadership leap in pharmaceuticals, driven by innovation and regulation.
- Annual turnover: ₹4.72 lakh crore (~USD 51 billion) as of FY25
- Global ranking: 3rd in pharmaceutical volumes and 11th in value
- Export growth: ~7% CAGR over the past decade
- Positioning: India has cemented its reputation as the “pharmacy of the world”
While the generics industry has been the engine of this robust rise, there is significant headroom to climb further up the value ladder. The more consequential opportunity lies in new chemical and biological entities, where the right research priorities and innovation could shift India from a reliable supplier to a breakthrough originator of pharmaceuticals.
How is India becoming a global drug discovery hub? The global pharmaceutical market is increasingly innovation-driven, with nearly two-thirds of value coming from patented drugs, biologics and advanced therapies.
- India’s pharmaceutical market is currently around USD 60 billion
- It is projected to reach USD120–130 billion by 2030
- By 2047, it will reach up to USD 450 billion
Capturing this potential will depend less on volume and more on innovation-led value creation.
Momentum is building. Indian companies are increasing R&D investments and expanding biologics pipelines, with over 40 NCEs and NBEs under development. Government initiatives like the National Biopharma Mission and the ₹10,000 crore Biopharma Shakti initiative are strengthening the ecosystem.
While India spends 0.6 percent of GDP on R&D, pharma companies invest around 4.5 percent, with leading firms at 6–7 percent of sales. CRDMOs further support this shift by enabling cost-efficient global R&D in advanced therapies such as gene therapies, ADG and, positioning India as an emerging innovation hub.
Is India Moving Fast Enough on Pharmaceutical Innovation?
Pharmaceutical Innovation is inherently high-risk and capital-intensive. Only about 10 percent of molecules entering clinical trials reach approval, with development timelines often extending a decade, and costs exceeding USD 1billion-USD 2 billion. In this context, regulatory clarity can bring a competitive advantage.
India currently accounts for only three to four percent of global clinical trials despite its advantages in patient diversity, disease burden, and cost. While approval timelines and processes are improving, there is scope to further strengthen consistency and alignment with global benchmarks.
The regulatory capacity is evolving alongside scientific complexity. The Central Drugs Standard Control Organisation (CDSCO) has taken steps to strengthen review frameworks, introduce expedited pathways and build expertise in areas like biologics & clinical pharmacology. These are important foundations for scaling innovation.
What Will it Take to Accelerate the Shift in Pharmaceutical Innovation?
Sustaining this momentum will require targeted shifts in how innovation is enabled and regulated by building frameworks that can keep pace with rapid scientific change.
- First, regulatory pathways must become more differentiated.
Innovative therapies require tailored evaluation frameworks, adaptive trial designs, and faster approval routes. Segregating these from generic pathways can significantly reduce time-to-market without compromising safety. - Second, stronger financial incentives are essential.
Given the high risk and long gestation periods of pharma R&D, measures such as enhanced tax deductions, a more effective patent-box regime, and schemes like ANRF and PLI can help crowd in private investment and de-risk innovation. - Third, digital infrastructure needs to be scaled.
Regulatory processes today remain fragmented, with limited data integration. A unified digital platform linking submissions, approvals, inspections, and pharmacovigilance could significantly improve efficiency, transparency, and real-time oversight.
Is India Positioned to Capture the Next Pharma Growth Cycle?
India’s long-term ambition is to build a USD 400-USD 450 billion pharmaceutical market by 2047 and become a significant contributor to global drug discovery. This includes increasing India’s share of global clinical trials to 10-15 percent and scaling domestic pipelines in novel therapies.
Encouragingly, Indian firms are advancing novel molecules into late-stage trials, biologics exports are growing and collaboration across industry, academia, and startups is expanding. Funding, including ₹5,000 crore national PRIP (Promotion of Research and Innovation in Pharma) fund through 2030, will also support this gradual shift.
India has demonstrated global leadership in generics. The next phase, to build innovation at scale, is more complex, but far more consequential. The transition from volume leadership is underway, but it requires urgency and sustained policy focus.
Innovation-led pharmaceuticals must now be treated as a core industrial priority. Countries that have made this shift have transformed their position in the global health economy. India has the capability, the momentum, and the opportunity. The task ahead is to act decisively and lead.
